PREVENT trial
Jump to navigation
Jump to search
Introduction
Subgroup analysis[1]
5600 hopsitalized patients at risk for venous thromboembolism
1118 obese patients, 1226 elderly
serum creatinine < 2.0
5000 U of dalteparin QD vs placebo
Combined endoint:
- symptomatic venous thromboembolism
- fatal pulmonary embolism
- sudden death
- proximal deep vein thrombosis by ultrasound
Results:
- endpoint reached
- obese:
- 2.8% of dalteparin group vs 4.3% in placebo group
- elderly
- 4.2% of dalteparin group vs 8.0% in placebo group
- obese:
- difference significant only for elderly
- mortality, hemorrhage, thrombocytopenia not different among groups
More general terms
Additional terms
References
- ↑ 1.0 1.1 Journal Watch 25(7):53, 2005 Kucher N, Leizorovicz A, Vaitkus PT, Cohen AT, Turpie AG, Olsson CG, Goldhaber SZ. Efficacy and safety of fixed low-dose dalteparin in preventing venous thromboembolism among obese or elderly hospitalized patients: a subgroup analysis of the PREVENT trial. Arch Intern Med. 2005 Feb 14;165(3):341-5. PMID: https://www.ncbi.nlm.nih.gov/pubmed/15710801